NHWA(SZ:002262) Ge Long Hui·2026-01-12 08:20Core Viewpoint - Enhua Pharmaceutical (002262.SZ) is currently in communication with the CDE regarding the Phase III clinical trial plan for NHL35700, which is expected to enter Phase III clinical trials in 2026 [1] Company Summary - Enhua Pharmaceutical is actively engaging with regulatory authorities to advance its clinical development program for NHL35700 [1] - The anticipated timeline for entering Phase III clinical trials is set for 2026, indicating a strategic focus on the drug's development [1] Industry Summary - The communication with the CDE reflects the ongoing regulatory processes within the pharmaceutical industry, particularly in the context of clinical trial advancements [1] - The expected timeline for clinical trials highlights the industry's emphasis on long-term planning and regulatory compliance in drug development [1]